Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV)(FSE: 7JO0) is pleased to announce the successful presentation of new data at the AACR-NCI-EORTC International Conference on Mol
(Financial Post, 2025-10-27T08:01:24Z)